July 6, 2012

Press Release

Mitsubishi Tanabe Pharma Corporation

Launch of Argatroban, a Selective Antithrombin Agent, in UK

Osaka, Japan, July 6, 2012—Mitsubishi Tanabe Pharma Corporation (hereafter, MTPC; President and CEO: Michihiro Tsuchiya) announced today that its consolidated subsidiary, Mitsubishi Pharma Europe Ltd. (hereafter, MPE; headquartered in London), began marketing argatroban monohydrate (hereafter argatroban), a selective antithrombin agent, in the UK.

In December 2011, MPE filed in the UK an application for approval of argatroban as a therapeutic for heparin-induced thrombocytopenia (HIT) type II by European mutual recognition procedure. In June 2012, following approval in March, the company launched the drug under the brand name Exembol®. Argatroban, a selective antithrombin agent discovered and developed by MTPC, is currently marketed under the brand name Novastan® HI Injection in Japan. Following first European approval in Sweden in 2004, it has been marketed as a new therapeutic for HIT-II in 11 countries, including France and Germany.

Heparin-induced thrombocytopenia (HIT) type II is a serious disease that can induce complicating fatal thromboembolism. Because argatroban has a short elimination half-life in the blood and undergoes hepatic metabolism, it is suitable for use as an anticoagulant for patients with HIT-II developing in perioperative settings or renal disease.

MTPC and MPE expect to establish a foundation for the marketing of their pharmaceuticals in the UK and other European countries and contribute to needs in clinical practice in these countries through providing argatroban.

<<Contact for Inquiries>>
Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Phone: +81-6-6205-5211